Department of Medicine, Allergy/Immunology Clinic, Keesler Medical Center, Biloxi, Mississippi 39534, USA.
Curr Opin Allergy Clin Immunol. 2013 Aug;13(4):365-71. doi: 10.1097/ACI.0b013e3283625144.
The purpose of this article is to provide a brief overview of the events involved in honeybee allergy and to concisely update the reader on progress toward knowledge of honeybee venom (HBV), strides in solving diagnostic difficulties, and advancements in improving safety and efficacy of HBV immunotherapy.
It is well known that honeybee allergy is unique in venom allergen and protein composition, diagnostic challenges, and immunotherapy safety and efficacy. Many new honeybee allergens have been recognized. Advances in testing, evaluation, and extract manipulation methods, many using recombinant technology, have allowed a greater ability to help with honeybee allergy diagnosis and resultant improvement in immunotherapy safety and evaluation of immunotherapy efficacy.
In an effort to address many honeybee allergy concerns, specific advances have been recently made. Some recently characterized honeybee allergens appear to be major contributors to honeybee allergy. In the setting of double-positivity, cross-reacting carbohydrate determinants and other cross-reacting components in HBV have made diagnosis of honeybee allergy challenging. Recombinant technology, including component-resolved diagnostics, and other evolving testing methods should help clarify double-positivity, if not now, in the very near future. Purified HBV and possibly depot formulations for immunotherapy appear to make it more well tolerated. Recombinant methods may help with evaluation of immunotherapy's safety and efficacy.
本文旨在简要概述蜜蜂过敏相关事件，并简要介绍有关蜜蜂毒液（HBV）的最新进展，包括解决诊断难题、提高 HBV 免疫治疗安全性和有效性方面的进展。
众所周知，蜜蜂过敏在毒液过敏原和蛋白组成、诊断挑战以及免疫治疗的安全性和有效性方面具有独特性。现已发现许多新的蜜蜂过敏原。检测、评估和提取物处理方法的进步，包括许多使用重组技术的方法，使得我们能够更好地帮助诊断蜜蜂过敏，并提高免疫治疗的安全性，评估免疫治疗的效果。
为了解决许多蜜蜂过敏相关问题，最近取得了一些特定的进展。一些最近被确定的蜜蜂过敏原似乎是蜜蜂过敏的主要原因。在双重阳性的情况下，HBV 中的交叉反应性碳水化合物决定簇和其他交叉反应成分使得蜜蜂过敏的诊断具有挑战性。重组技术，包括基于成分的诊断和其他正在发展的检测方法，应该有助于澄清双重阳性，如果不是现在，也将在不久的将来。纯化的 HBV 以及免疫治疗的可能储存制剂似乎使其更耐受。重组方法可能有助于评估免疫治疗的安全性和有效性。
